http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
Mipsagargin Demonstrates Clinical Benefit in Subset of Glioblastoma Patients
-
GenSpera Provides Update on Clinical Development Programs
-
World-Renowned Neuro-Oncologist Santosh Kesari, MD, PhD Joins GenSpera’s Scientific Advisory Board
-
GenSpera to Present at the BIO Investor Forum
-
GenSpera Announces Encouraging Interim Phase II Data for Glioblastoma, Showcases Positive Future for Mipsagargin Across Multiple Types of Solid Tumors
-
GenSpera to Present at Rodman & Renshaw 17th Annual Global Investment Conference
-
GenSpera Provides 2nd Quarter Corporate Update
-
GenSpera Phase II Abstract Accepted for Presentation at the Society of Neuro-Oncology 20th Annual Scientific Meeting
-
U.S. Court of Appeals Enters Judgment in Favor of GenSpera
-
Patent Application for GenSpera Partner Phyton Biotech Is Published by World Intellectual Property Organization (WIPO)
-
GenSpera Announces Private Placement of $2.5 Million
-
U.S. Food and Drug Administration's Office of Orphan Products Development Issues Grant Supporting GenSperas Glioblastoma Study
-
Craig A. Dionne to Speak at BIO International 2015
-
KTLA TV's Health Smart Showcases GenSpera's Cancer Research
-
GenSpera's CEO Craig A. Dionne Interviewed on Sirius Radio
-
GenSpera's CEO Craig A. Dionne to Present H.C. Wainwright & Co.'s Panel Discussion during ASCO 2015
-
GenSpera Expands Phase II Glioblastoma Trial of Mipsagargin
-
GenSpera Provides Corporate Update
-
GenSpera Enters National Phase with Patent Application for Injectable Prodrug Formulations
-
GenSpera Granted New Patent for Prodrugs Activated by Prostate Specific Antigen
-
GenSpera Launches National Investor Relations Program
-
GenSpera Presents at BIO Asia International Conference

